title: Effects of FL-386 on faecal lipid excretion in humans.
abstract: A newly synthesized inhibitor of pancreatic lipase and micelle formation, FL-386, was administered at a dose of 400 mg (in the diet, for seven consecutive days) to nine healthy adult volunteers, and changes in faecal mass, frequency of defaecation, and properties of the stools were observed. High performance liquid chromatography and gas-liquid chromatography were used to analyse the faeces for short-chain carboxylic acids, neutral sterols, bile acids, fats and hydroxyfatty acids. FL-386 had little effect on the amounts and composition of short-chain carboxylic acids, neutral sterols, and bile acids excreted, nor did it produce changes in the composition of fatty acids, or the percentages of hydroxyfatty acids in the stool. However, in those patients treated with FL-386, the faecal mass was increased, and stools were softer and contained increased amounts of fatty acids. The compound did not produce particularly fatty stools. It was concluded that FL-386 induces slight disturbance in the digestion and absorption of dietary lipids.
authors.affiliation: Third Department of Internal Medicine, Hirosaki University School of Medicine, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Nakamura
authors.forename: K
authors.initials: K
authors.lastname: Takebe
authors.forename: N
authors.initials: N
authors.lastname: Yamada
authors.forename: Y
authors.initials: Y
authors.lastname: Arai
authors.forename: Y
authors.initials: Y
authors.lastname: Tandoh
authors.forename: A
authors.initials: A
authors.lastname: Terada
authors.forename: M
authors.initials: M
authors.lastname: Ishii
authors.forename: K
authors.initials: K
authors.lastname: Kudoh
authors.forename: H
authors.initials: H
authors.lastname: Kikuchi
authors.forename: K
authors.initials: K
authors.lastname: Machida
mesh_terms: D000328:Adult; D001557:Benzenesulfonates / Q000008:administration & dosage / Q000494:pharmacology*; D001647:Bile Acids and Salts / Q000032:analysis / Q000378:metabolism; D002264:Carboxylic Acids / Q000378:metabolism; D002851:Chromatography, High Pressure Liquid; D003672:Defecation / Q000187:drug effects; D004032:Diet; D002149:Energy Intake; D005227:Fatty Acids / Q000032:analysis / Q000378:metabolism; D005243:Feces / Q000737:chemistry*; D005989:Glycerides / Q000378:metabolism; D006801:Humans; D000960:Hypolipidemic Agents / Q000494:pharmacology*; D008049:Lipase / Q000037:antagonists & inhibitors; D050356:Lipid Metabolism; D008055:Lipids / Q000032:analysis; D010179:Pancreas / Q000201:enzymology; D013261:Sterols / Q000378:metabolism
chemical_list: D001557:Benzenesulfonates; D001647:Bile Acids and Salts; D002264:Carboxylic Acids; D005227:Fatty Acids; D005989:Glycerides; D000960:Hypolipidemic Agents; D008055:Lipids; D013261:Sterols; C058877:2-(4-isobutylcyclohexyl)-2-oxoethyl benzenesulfonate; D008049:Lipase